Excoso

Excoso is a Czech biotechnology company and a key research and intellectual property entity within the PPF Group's life sciences portfolio. Closely integrated with SOTIO Biotech, Excoso focuses on the discovery and early-stage development of innovative cancer immunotherapies, including antibody-drug conjugates (ADCs), next-generation immunocytokines, and cell-based therapies. The company holds the foundational patents for several high-profile assets, such as the PD-1-targeting immunocytokine SOT201 and various ADC programs targeting solid tumors. Based in Prague, Excoso leverages collaborations with global technology partners and its parent group's manufacturing capabilities to advance a diverse pipeline of oncology treatments. Its work is central to the group's mission of translating complex science into effective clinical solutions for patients with hard-to-treat cancers.